🔬 The system meets Grade A standards, ensuring precision in sterile liquid manufacturing.
📈 CEO Colin MacKay states that this upgrade boosts technical capabilities to meet rising demand.
📅 Production is set to begin in Q4 2025, with capacities of 15,000 vials per batch.
Introduction:
This article discusses the recent advancement by Symbiosis Pharmaceutical Services in enhancing their sterile manufacturing capabilities through the qualification of a new automated fill/finish line at their facility in Stirling, Scotland. This milestone is significant given the increasing demand for high-quality sterile manufacturing solutions in the biopharmaceutical sector.
- Symbiosis has successfully qualified a new automated fill/finish line, the FPD 50 Flexicon, in their Stirling production facility.
- The fill/finish line operates under a Grade A Restricted Access Barrier System (RABS), ensuring high standards of sterility.
- The system includes rapid transfer ports for aseptic handling and advanced vials filling technology, which enhances precision and efficiency in production.
- CEO Colin MacKay emphasized the importance of this advancement in meeting the growing demand for sterile manufacturing and aiding clients in delivering vital therapies.
- Commercial production is expected to commence in the fourth quarter of 2025, with the capacity to produce batches of up to 15,000 vials.
Conclusion:
The qualification of the new automated fill/finish line significantly expands the sterile manufacturing capacity of Symbiosis, allowing for the swift and compliant production of essential therapies. This initiative positions the company to better respond to market demands and supports the ongoing development of the biopharmaceutical industry.
